Navigation Links
NewBridge Pharmaceuticals Announces Licensing of Pylera(R) for Middle East, Africa, Turkey & Caspian Region
Date:7/22/2009

ss sales and marketing, pharmacovigilance and supply chain support for our innovative products allows patients and physicians across the region access to best-in-class therapeutics, education and support."

"We are happy to be partnering with NewBridge Pharmaceuticals," said Nicholas Franco, Axcan's Senior Vice President, International Commercial Operations, "which will enable Axcan's Pylera to be launched in rapidly growing markets in which NewBridge has expertise."

About Helicobacter pylori

The discovery in 1983 of the Helicobacter pylori organism was one of the major advances in gastroenterology in recent decades, as it has revolutionized the approach to many upper gastrointestinal disorders. Helicobacter pylori is believed to cause a spectrum of diseases in humans, including gastritis, ulcer disease (gastric and duodenal), gastric cancer and gastric lymphoma. In North-America, 10% of the population will have an ulcer in their lifetime; and many treatments end up with a high rate of recurrences. In fact, 40% to 80% of patients experience a recurrence within only a year after undergoing short-term treatment of gastric acid suppression therapy. Studies have shown that the gastroduodenal reoccurrence rate is only 2% for patients in whom the organism has been eradicated.

About NewBridge Pharmaceuticals

NewBridge Pharmaceuticals (www.nbpharma.com) is a specialty pharmaceutical, biologics, and medical device company serving the Middle East, Africa, Turkey, and Caspian regions to address the unmet needs of diseases with high regional prevalence such as cancer, diabetes, obesity, cardiovascular diseases and other metabolic disorders. NewBridge in-licenses and commercializes FDA and EMEA approved therapeutics, medical devices and diagnostics. Headquartered in UAE with Business Development in the US, NewBridge was founded in 2007 by Burrill & Comp
'/>"/>

SOURCE NewBridge Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Newbridge Securities Corporation Forms BioVentures Division
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... This is a professional and in-depth ... The report provides basic biocides information, including its ... well as industry overview. This research covers the ... well as Global industry analysis covering macroeconomic environment ... Chinese biocides industry covers information on ...
(Date:10/31/2014)... ENVIRON , an international ... that Dr. Harvey Clewell III has rejoined the ... closely with senior professionals in ENVIRON’s Health Sciences ... at The Hamner Institutes for Health Sciences (The ... he is Director, Center for Human Health Assessment. ...
(Date:10/31/2014)... , Oct. 31, 2014  Atlanta-based Intellimedix could ... accompanying the onset of Ebola by suggesting a ... at Georgia Tech,s Center for Computational Systems Biology ... to find alternative uses for existing drugs through ... to aid the bout against Ebola. ...
(Date:10/30/2014)... 30, 2014  Ardelyx, Inc. (NASDAQ: ... cardio-renal, gastrointestinal and metabolic diseases, today announced that ... on Thursday, November 6, 2014. Following the announcement, ... conference call and webcast at 4:30pm ET to ... business update. The live webcast can ...
Breaking Biology Technology:Biocides Market for International & Chinese Regional Development Analysis Now Available at DeepResearchReports.com 2Biocides Market for International & Chinese Regional Development Analysis Now Available at DeepResearchReports.com 3Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3Atlanta-Based Intellimedix May Help Solve Ebola With Computer Algorithms 2Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2
... , , , , ... CA and Ottawa, Ontario), a clinical stage biopharmaceutical company developing a ... the Second and final closing of a private placement financing with ... $5 million. , , As previously reported, ...
... CINCINNATI, Sept. 18 LCA-Vision Inc. (Nasdaq: LCAV ... the Lasik Plus (R) brand, announces that Steven C. Straus ... the company,s board of directors effective September 25, 2009 to ... Management of daily operations will be the responsibility of Chief ...
... 18 Omeros Corporation today announced the launch of its ... stock. Omeros is a clinical-stage biopharmaceutical company committed to ... of the central nervous system. , , ... $10.00 to $12.00 per share. Omeros has applied to ...
Cached Biology Technology:Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million 2Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million 3LCA-Vision Announces CEO Resignation 2Omeros Commences Initial Public Offering of Common Stock 2Omeros Commences Initial Public Offering of Common Stock 3
(Date:10/29/2014)... hair as a consequence of chemotherapy will benefit from ... cooling technology that prevents hair loss. , The research ... global scalp cooling manufacturing company, Paxman Coolers, of Fenay ... the University of Huddersfield. , The research will be ... background in the pharmacology of cancer treatment, which he ...
(Date:10/29/2014)... for the Society of Interventional Radiology,s (SIR) ... the one place where interventional radiologists, diagnostic ... professionals can come together to find the ... presented, discussed and tested. , "Connecting ... medicine, SIR 2015 will feature essential updates ...
(Date:10/29/2014)... industrial products are in the environment – and hundreds ... scientists have yet to determine whether they cause health ... that by estimating which substances people are exposed to ... ACS journal Environmental Science & Technology . , ... to human health of any given substance depend primarily ...
Breaking Biology News(10 mins):New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2SIR 2015: Interventional radiology shapes tomorrow's medicine 2
... University, the team mapped the presence of foxes in ... their likely distribution as a blueprint for fox eradication, ... of Canberra professor in wildlife genetics and leader of ... northern and eastern Tasmania and the model developed by ...
... CA Researchers from the Carnegie Institution are rolling out ... AToMS, for the first time at the American Geophysical ... and its scientific observations are uncovering a previously invisible ... is helping researchers look at the world in a ...
... MA and SAN FRANCISCO, CADecember 4, 2012 The ALS ... today announced the formation of a research collaboration to ... the preclinical drug development process. "We are ... ALS therapeutic development," said Steve Perrin, PhD, CEO and ...
Cached Biology News:Fox invasion threatens wave of extinction, UC research finds 2Carnegie debuts revolutionary biosphere mapping capability at AGU 2Carnegie debuts revolutionary biosphere mapping capability at AGU 3ALS TDI and Gladstone Institutes collaborate to discover potential ALS treatments 2
Bio-Plex Manager software, version 3.0, 5 license netshare, is a five-user software package that provides access to data from the Bio-Plex suspension array system from a server. This version does not...
... 3 x 3 nmol (individual) with ... 3 siRNAs specifically targeted to your target gene ... reagent guarantees you get more than 75% knockdown ... conditions (100 nM siRNA for transfection and confirmation ...
... siTrio siRNA --- a cocktail of 3 ... of interestis our most popular product. The ... 75% knockdown of your target gene when ... for transfection and confirmation of optimal transfection ...
... IDS 25-Hydroxy Vitamin D kit is ... determination of 25-hydroxyvitamin D (25-OH D) ... serum or plasma. Our patented DIRECT ... solvent precipitation and centrifugation and therefore ...
Biology Products: